Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.

Ozempic and other semaglutide medications have skyrocketed in popularity as weight-loss aids, with prescriptions surging by ...